Abstract
Current medical literature clearly defines a group of low-risk papillary thyroid carcinomas that may be treated effectively with thyroid lobectomy alone. Considerations regarding overall survival, local control, and perioperative morbidity in addition to patient monitoring, disease features, and patient preference, guide the treatment team in the extent of surgical intervention. The effectiveness of thyroid lobectomy for papillary thyroid carcinoma is dependent upon accurate preoperative and intraoperative exclusion of bilateral disease, extrathyroidal extension, or nodal metastasis. The advantages over total thyroidectomy are reduced perioperative morbidity and less dependence upon thyroid hormone replacement. The disadvantages are more dependence upon ultrasound surveillance, inability to use radioiodine, and potential need for completion thyroidectomy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Works Cited
Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–5; discussion 605–7.
Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81; discussion 381–4.
Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:901–11.
Erdem E, Gulcelik MA, Kuru B, Alagol H. Comparison of completion thyroidectomy and primary surgery for differentiated thyroid carcinoma. Eur J Surg Oncol. 2003;29:747–9.
Grant CS, Hay ID, Gough IR, Bergstralh EJ, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104:954–62.
Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81–9.
Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844–52.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64; discussion 964–6.
Leiker AJ, Yen TW, Cheung K, Evans DB, Wang TS. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of “suspicious for papillary thyroid cancer”. Surgery. 2013;154:1307–13; discussion 1313–4.
Marino M, Spencer H, Hohmann S, Bodenner D, Stack Jr BC. Costs of outpatient thyroid surgery from the University HealthSystem Consortium (UHC) database. Otolaryngol Head Neck Surg. 2014;150(5):762–9. doi:10.1177/0194599814521583. Epub 2014 Feb 4.
Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79.
Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.
Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61.
Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.
Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011;75:112–9.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
Kiernan CM, Parikh AA, Parks LL, etal. Use of Radioiodine after Thyroid Lobectomy in patients with differentiates Thyroid Cancer. Does it change outcome? J Am Coll Surg. 04/2015;220(4).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mark, J., Steward, D.L. (2017). Surgical Management of Low-Risk Papillary Thyroid Cancer. In: Roman, S., Sosa, J., Solórzano, C. (eds) Management of Thyroid Nodules and Differentiated Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-43618-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-43618-0_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43616-6
Online ISBN: 978-3-319-43618-0
eBook Packages: MedicineMedicine (R0)